Cargando…

KSI-301: antibody biopolymer conjugate in retinal disorders

KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Priya R., Madanagopalan, V.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278447/
https://www.ncbi.nlm.nih.gov/pubmed/34291186
http://dx.doi.org/10.1177/25158414211027708
_version_ 1783722262014197760
author Chandrasekaran, Priya R.
Madanagopalan, V.G.
author_facet Chandrasekaran, Priya R.
Madanagopalan, V.G.
author_sort Chandrasekaran, Priya R.
collection PubMed
description KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far have shown promising results in retinal vascular diseases. When using anti-VEGF agents for treatment of retinal disorders, the frequency of injections and follow-up visits has increased the treatment burden, greatly affecting the treatment outcome. There are new anti-VEGF agents in the horizon with extended duration of action, durability, safety profile and efficacy, which seem to address the above issues. PubMed search and Medline search were performed on newer anti-VEGF agents, KSI-301, antibody biopolymer conjugate in retina, KODIAK KSI-301, DAZZLE study, GLEAM study, GLIMMER study, GLOW study and BEACON study. This review article showcases the biophysical properties and ongoing trials related to KSI-301. Moreover, we discuss the efficacy and safety profile of KSI-301 on the basis of the results of available trials.
format Online
Article
Text
id pubmed-8278447
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82784472021-07-20 KSI-301: antibody biopolymer conjugate in retinal disorders Chandrasekaran, Priya R. Madanagopalan, V.G. Ther Adv Ophthalmol Review KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far have shown promising results in retinal vascular diseases. When using anti-VEGF agents for treatment of retinal disorders, the frequency of injections and follow-up visits has increased the treatment burden, greatly affecting the treatment outcome. There are new anti-VEGF agents in the horizon with extended duration of action, durability, safety profile and efficacy, which seem to address the above issues. PubMed search and Medline search were performed on newer anti-VEGF agents, KSI-301, antibody biopolymer conjugate in retina, KODIAK KSI-301, DAZZLE study, GLEAM study, GLIMMER study, GLOW study and BEACON study. This review article showcases the biophysical properties and ongoing trials related to KSI-301. Moreover, we discuss the efficacy and safety profile of KSI-301 on the basis of the results of available trials. SAGE Publications 2021-07-12 /pmc/articles/PMC8278447/ /pubmed/34291186 http://dx.doi.org/10.1177/25158414211027708 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Chandrasekaran, Priya R.
Madanagopalan, V.G.
KSI-301: antibody biopolymer conjugate in retinal disorders
title KSI-301: antibody biopolymer conjugate in retinal disorders
title_full KSI-301: antibody biopolymer conjugate in retinal disorders
title_fullStr KSI-301: antibody biopolymer conjugate in retinal disorders
title_full_unstemmed KSI-301: antibody biopolymer conjugate in retinal disorders
title_short KSI-301: antibody biopolymer conjugate in retinal disorders
title_sort ksi-301: antibody biopolymer conjugate in retinal disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278447/
https://www.ncbi.nlm.nih.gov/pubmed/34291186
http://dx.doi.org/10.1177/25158414211027708
work_keys_str_mv AT chandrasekaranpriyar ksi301antibodybiopolymerconjugateinretinaldisorders
AT madanagopalanvg ksi301antibodybiopolymerconjugateinretinaldisorders